Halozyme Therapeutics, Inc. · NASDAQ:HALO
Halozyme Therapeutics — Corporate Update (October 2025)
12 slides from Halozyme Therapeutics's corporate update, Oct 14, 2025
Slide 1: CMS Final IPAY 2028 Guidance for the IRA Medicare Negotiations Halozyme Position Statement
1 CMS Final IPAY 2028 Guidance for the IRA Medicare Part B Price Negotiations Halozyme Position Statement
Slide 2: Forward Looking Statements
2 Forward Looking Statements In addition to historical information, the statements set forth in this presentation include forward-looking statements including, without limitation, statements concerning the Company’s expected future financial performance, including the Company’s expectations of the i
Slide 3: Table of Contents
3 Table of Contents • CMS Final IPAY 2028 Guidance for the IRA Medicare Part B Price Negotiations • CMS Response to Comments Related to Fixed Combination Drugs; pages 15-16 • Halozyme Demonstration of Savings to Medicare and Meaningful Patient Benefits • U.S. Medicare Part B Spend % of Total ENHANZE
Slide 4: Summary
4 Summary • CMS final comments communicate no impact to IPAY Part B policy for fixed combination products until 2029 at earliest, if CMS were to finalize such a policy • Strong clinical and pharmacoeconomic evidence of benefit of SC administration of ENHANZE® partner products demonstrated • Halozyme
Slide 5: CMS Response to Comments Related to Fixed Combination Drugs
5 CMS Final IPAY 2028 Guidance for the IRA Medicare Part B Price Negotiations CMS Response to Comments Related to Fixed Combination Drugs; pages 15-16 Response: CMS thanks the commenters for their feedback on how the existing fixed combination drug policy could impact negotiation eligibility and sel
Slide 6: Halozyme Clinical & Pharmacoeconomic Research Demonstrated SC Delivery Savings and Benefits
6 Halozyme Clinical & Pharmacoeconomic Research Demonstrated that SC Delivery, Including With ENHANZE®, Resulted in Savings to Medicare and Clinically Meaningful Benefits Medicare Savings • Halozyme published peer reviewed study in Journal of Medical Economics (2025) that SC delivery of 5 of 7 biolo
Slide 7: SC Delivery of Biologic Drugs Resulted in Meaningful Cost Savings to Medicare Compared with IV
7 SC Delivery of 5 of 7 Biologic Drugs Resulted in Meaningful Cost Savings to Medicare Compared with IV Delivery of Same Drugs Comparison of utilization and total Medicare fee-for service expenditures for subcutaneous versus intravenous versions of select group of therapies; Peter Kardel, Caitlin Sh
Slide 8: SC Delivery With ENHANZE Results in Clinically Meaningful Benefits
8 SC Delivery With ENHANZE® Results in Clinically Meaningful Benefits When compared to an antibody given intravenously as a single component product, subcutaneous delivery of a fixed combination containing Halozyme’s human hyaluronidase and the specific antibody can enable, for example: • Meaningful
Slide 9: SC Delivery Preferred by 89.6% Patients Versus 5.5% for IV
9 SC Delivery Preferred by 89.6% Patients Versus 5.5% for IV Real-World Quantitative Insights into the Treatment Experience of Patients with Cancer in the USA with Subcutaneous Versus Intravenous Drug Delivery Robert Epstein · JoAnn Krenitsky · Phillip Sarocco Oncol Ther. 2025 Sep;13(3):695-710. doi
Slide 10: IPAY 2028 Final Guidance Projected to Result in Zero Negotiation Impact in 2028
10 IPAY 2028 Final Guidance Projected to Result in Zero Part B Price Negotiation Impact in 2028 12023 and 2024 Total ENHANZE® partner product global SC sales based on partner royalty reports, 2025-2028 reflects SC sales projections based on approved ENHANZE® products and assumes global approval and
Slide 11: Halozyme Projects Minimal, to No, Impact to Future Royalty Revenue
11 Halozyme Projects Minimal, to No, Impact to Future Royalty Revenue As a Result of IPAY 2028 Guidance for the IRA Medicare Part B Price Negotiations Zero Projected Royalty Revenue Impact for 2028 • No impact in 2028 due to no changes to IPAY Part B policy for fixed combination products until 2029
Slide 12: Our Vision: Breakthrough therapies will fit the patient's life
12 Today Many breakthrough therapies require the patient’s life to fit the treatment Our Vision Breakthrough therapies will fit the patient’s life Extends Halozyme’s Vision and Broadens Offerings in Drug Delivery Halozyme is committed to continue clinical and pharmacoeconomic research to demonstrate
Halozyme Therapeutics — Corporate Update (October 2025) on 6ix